Generation of predictive pharmacophore model for SARS-coronavirus main proteinase

European Journal of Medicinal Chemistry

Volumn 40, Issue 1, 2005, Pages 57-62

  Zhang, Xue Wu ^a   Yap, Yee Leng ^a   Altmeyer, Ralf M ^a  

^a HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

Author keywords

Drug design; Pharmacophore; SARs CoV; Virtual screening

Indexed keywords

ANTIVIRUS AGENT; ARAURIDINE; AZAURIDINE; BROMODEOXYCYTIDINE; BROXURIDINE; COFORMYCIN; CORDYCEPIN; CYTARABINE; DEOXYGUANOSINE; EMANIL; FIALURIDINE; FLOXURIDINE; GEMCITABINE; PIRAZOFURIN; PROTEINASE; PUROMYCIN; RIBAVIRIN; SPONGOTHYMIDIN; THYMIDINE; THYMINE ARABINOSIDE; TOYOCAMYCIN; TRICIRIBINE; TRIFLURIDINE; TUBERCIDIN; VIDARABINE PHOSPHATE; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; EXPERIMENT; PHARMACOPHORE; SEVERE ACUTE RESPIRATORY SYNDROME;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; MODELS, MOLECULAR; MOLECULAR MIMICRY; PEPTIDE HYDROLASES; PEPTIDES; PURINE NUCLEOSIDES; PYRIMIDINE NUCLEOSIDES; SARS VIRUS; VIRAL PROTEINS;

EID: 11844290106     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2004.09.013     Document Type: Article

References (27)

1. T.W. Lew, T.K. Kwek, D. Tai, A. Earnest, S. Loo, and K. Singh Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome J. Am. Med. Assoc. 290 3 2003 374 380
2. K.S. Chan, S.T. Lai, C.M. Chu, E. Tsui, C.Y. Tam, and M.M. Wong Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study Hong Kong Med. J. 9 6 2003 399 406
3. C.M. Chu, V.C. Cheng, I.F. Hung, M.M. Wong, K.H. Chan, K.S. Chan HKU/UCH SARS Study Group Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Thorax 59 3 2004 252 256
4. J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, and H.W. Doerr Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus Lancet 361 2003 2045 2046
5. D.L. Barnard, V.D. Hubbard, J. Burton, D.F. Smee, J.D. Morrey, and M.J. Otto Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-d-N4-hydroxycytidine Antiviral Chem. Chemother. 15 1 2004 15 22
6. J.S. Mason, A.C. Good, and E.J. Martin 3-D pharmacophores in drug discovery Curr. Pharm. Des. 7 7 2001 567 597
7. O. Dror, A. Shulman-Peleg, R. Nussinov, and H.J. Wolfson Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design Curr. Med. Chem. 11 1 2004 71 90
8. N. Neamati, H. Hong, A. Mazumder, S. Wang, S. Sunder, and M.C. Nicklaus Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching J. Med. Chem. 40 6 1997 942 951
9. H. Hong, N. Neamati, S. Wang, M.C. Nicklaus, A. Mazumder, and H. Zhao Discovery of HIV-1 integrase inhibitors by pharmacophore searching J. Med. Chem. 40 6 1997 930 936
10. H. Hong, N. Neamati, H.E. Winslow, J.L. Christensen, A. Orr, and Y. Pommier Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore Antiviral Chem. Chemother. 9 6 1998 461 472
11. M.C. Nicklaus, N. Neamati, H. Hong, A. Mazumder, S. Sunder, and J. Chen HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching J. Med. Chem. 40 6 1997 920 929
12. O.O. Clement, C.M. Freeman, R.W. Hartmann, V.D. Handratta, T.S. Vasaitis, and A.M. Brodie Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy J. Med. Chem. 46 12 2003 2345 2351
13. A.K. Debnath Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors J. Med. Chem. 46 21 2003 4501 4515
14. P.A. Keller, C. Birch, S.P. Leach, D. Tyssen, and R. Griffith Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor J. Mol. Graph Model. 21 5 2003 365 373
15. J. Faragalla, J. Bremner, D. Brown, R. Griffith, and A. Heaton Comparative pharmacophore development for inhibitors of human and rat 5-alpha-reductase J. Mol. Graph Model. 22 1 2003 83 92
16. M.R. Doddareddy, H.K. Jung, J.Y. Lee, Y.S. Lee, Y.S. Cho, and H.Y. Koh First pharmacophoric hypothesis for T-type calcium channel blockers Bioorg. Med. Chem. 12 7 2004 1605 1611
17. G.I. Mustata, A. Brigo, and J.M. Briggs HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors Bioorg. Med. Chem. Lett. 14 6 2004 1447 1454
18. H. Sun, D.N. Greeley, X.J. Chu, A. Cheung, W. Danho, and J. Swistok A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides Bioorg. Med. Chem. 12 10 2004 2671 2677
19. H. Yang, M. Yang, Y. Ding, Y. Liu, Z. Lou, and Z. Zhou The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Proc. Natl. Acad. Sci. USA 100 2003 13190 13195
20. X.W. Zhang, and Y.L. Yap Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs Bioorg. Med. Chem. 12 10 2004 2517 2521
21. R. Wang, Y. Gao, and L. Lai LigBuilder: a multipurpose program for structure-based drug design J. Mol. Model. (Online) 6 2000 498 516
22. G.I. Mustata, and J.M. Briggs A structure-based design approach for the identification of novel inhibitors: application to an alanine racemase J. Comput. Aided Mol. Des. 16 12 2002 935 953
23. Y. Kliger, and E.Y. Levanon Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy BMC Microbiol. 3 2003 20 26
24. X.W. Zhang, and Y.L. Yap Structural similarity between HIV-1 gp41 and SARS-CoV S2 proteins suggests an analogous membrane fusion mechanism J. Mol. Struct. (Theochem.) 677 2004 73 76
25. M. Robertson FgI2: link between hepatitis B and SARS? Drug Discov. Today 8 2003 768 770
26. X.W. Zhang, and Y.L. Yap Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design Bioorg. Med. Chem. 12 2004 2219 2223
27. J. Oxford, S. Balasingam, and R. Lambkin A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community J. Antimicrob. Chemother. 53 2 2004 133 136